CoChat
Sign Up
Cited by 106

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Recruitment and activation of type 3 innate lymphoid cells promote antitumor immune responses

Bruchard, Mélanie, Geindreau, Mannon, Perrichet, Anaïs, Truntzer, Caroline, Ballot, Elise, Boidot, Romain, Racoeur, Cindy, Barsac, Emilie, Chalmin, Fanny, Hibos, Christophe, Baranek, Thomas, Paget, Christophe, Ryffel, Bernhard, Rébé, Cédric, Paul, Catherine, Végran, Frédérique, Ghiringhelli, François·2022·Nature Immunology
DOI 10.1038/s41590-021-01120-y
Open this paper in CoChat — free account

Abstract

Tumors poorly infiltrated by T cells are more resistant to immunogenic chemotherapies and checkpoint inhibition than highly infiltrated tumors. Using murine models, we found that CCR6 + type 3 innate lymphoid cells (ILC3s) can trigger an increase in the number of T cells infiltrating a tumor. Shortly after administration of cisplatin chemotherapy, production of the chemokine CCL20 and proinflammatory cytokine IL-1β at the tumor site led to the recruitment and activation of ILC3s. Within the tumor, ILC3 production of the chemokine CXCL10 was responsible for the recruitment of CD4 + and CD8 + T lymphocytes to the tumor. ILC3-dependent infiltration of T cells was essential for antitumor immune responses and increased the efficacy of checkpoint inhibition. Thus, we reveal an essential role of CCL20 and IL-1β, which promote ILC3-dependent antitumor immunity and enhance tumor sensitivity to immunotherapy.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41590-021-01120-y

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • CXCL10 can recruit lymphocytes, including Th1 and Th17 cells, to inflammatory sites, thereby amplifying local immune responses.

    “Notably, CXCL10 can recruit lymphocytes, including Th1 and Th17 cells, to inflammatory sites, thereby amplifying local immune responses46,47.”

    From Macrophage INSIG1 deficiency drives psoriasiform dermatitis via the SREBP2-STAT1 axis (2026) · cites this paper as [46]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 37

  1. Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960–1964 (2006). · DOI · Paper page
  2. Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014). · DOI · Paper page
  3. Matsutani, S. et al. Significance of tumor-infiltrating lymphocytes before and after neoadjuvant therapy for rectal cancer. Cancer Sci. 109, 966–979 (2018). · DOI
  4. Irshad, S. et al. RORγt+ innate lymphoid cells promote lymph node metastasis of breast cancers.Cancer Res. 77, 1083–1096 (2017). · DOI
  5. Eisenring, M., vom Berg, J., Kristiansen, G., Saller, E. & Becher, B. IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46. Nat. Immunol. 11, 1030–1038 (2010). · DOI
  6. Nussbaum, K. et al. Tissue microenvironment dictates the fate and tumor-suppressive function of type 3 ILCs. J. Exp. Med. 214, 2331–2347 (2017). · DOI
  7. Dieu-Nosjean, M.-C. et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J. Clin. Oncol. 26, 4410–4417 (2008). · DOI
  8. Ben-Sasson, S. Z. et al. IL-1 enhances expansion, effector function, tissue localization, and memory response of antigen-specific CD8 T cells. J. Exp. Med. 210, 491–502 (2013). · DOI
  9. Voronov, E. & Apte, R. N. IL-1 in colon inflammation, colon carcinogenesis and invasiveness of colon cancer. Cancer Microenviron. 8, 187–200 (2015). · DOI
  10. Mortha, A. et al. Microbiota-dependent crosstalk between macrophages and ILC3 promotes intestinal homeostasis. Science 343, 1249288 (2014). · DOI · Paper page
  11. Zhou, L. et al. Innate lymphoid cells support regulatory T cells in the intestine through interleukin-2. Nature 568, 405–409 (2019). · DOI
  12. Hirota, K. et al. Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J. Exp. Med. 204, 2803–2812 (2007). · DOI · Paper page
  13. Kleinewietfeld, M. et al. CCR6 expression defines regulatory effector/memory-like cells within the CD25+CD4+ T-cell subset. Blood 105, 2877–2886 (2005). · DOI
  14. Ito, T., Carson, W. F., Cavassani, K. A., Connett, J. M. & Kunkel, S. L. CCR6 as a mediator of immunity in the lung and gut. Exp. Cell. Res. 317, 613–619 (2011). · DOI
  15. Li, Z. et al. Epidermal Notch1 recruits RORγ+ group 3 innate lymphoid cells to orchestrate normal skin repair. Nat. Commun. 7, 11394 (2016). · DOI
  16. Withers, D. R. et al. Transient inhibition of ROR-γt therapeutically limits intestinal inflammation by reducing TH17 cells and preserving group 3 innate lymphoid cells. Nat. Med. 22, 319–323 (2016). · DOI
  17. Huh, J. R. et al. Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORγt activity. Nature 472, 486–490 (2011). · DOI
  18. Xiao, S. et al. Small-molecule RORγt antagonists inhibit T helper 17 cell transcriptional network by divergent mechanisms. Immunity 40, 477–489 (2014). · DOI
  19. Mebius, R. E., Rennert, P. & Weissman, I. L. Developing lymph nodes collect CD4+CD3- LTbeta+ cells that can differentiate to APC, NK cells, and follicular cells but not T or B cells. Immunity 7, 493–504 (1997). · DOI
  20. Carrega, P. et al. NCR+ ILC3 concentrate in human lung cancer and associate with intratumoral lymphoid structures. Nat. Commun. 6, 8280 (2015). · DOI
  21. Takatori, H. et al. Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22. J. Exp. Med. 206, 35–41 (2009). · DOI
  22. Godec, J. et al. Compendium of immune signatures identifies conserved and species-specific biology in response to inflammation. Immunity 44, 194–206 (2016). · DOI
  23. Paget, C. et al. CD3bright signals on γδ T cells identify IL-17A-producing Vγ6Vδ1+ T cells. Immunol. Cell Biol. 93, 198–212 (2015). · DOI
  24. Koh, J. et al. IL23-producing human lung cancer cells promote tumor growth via conversion of innate lymphoid cell 1 (ILC1) into ILC3. Clin. Cancer Res. 25, 4026–4037 (2019). · DOI
  25. Munneke, J. M. et al. Activated innate lymphoid cells are associated with a reduced susceptibility to graft-versus-host disease. Blood 124, 812–821 (2014). · DOI
  26. Trabanelli, S. et al. CD127+ innate lymphoid cells are dysregulated in treatment naïve acute myeloid leukemia patients at diagnosis. Haematologica 100, e257–e260 (2015). · DOI
  27. Kuo, P. T. et al. The role of CXCR3 and its chemokine ligands in skin disease and cancer. Front. Med. 5, 271 (2018). · DOI
  28. Sato, Y. et al. CXCL10 expression status is prognostic in patients with advanced thoracic esophageal squamous cell carcinoma. Ann. Surg. Oncol. 23, 936–942 (2016). · DOI
  29. Sonnenberg, G. F., Monticelli, L. A., Elloso, M. M., Fouser, L. A. & Artis, D. CD4+ lymphoid tissue-inducer cells promote innate immunity in the gut. Immunity 34, 122–134 (2011). · DOI
  30. Ranasinghe, R. & Eri, R. Modulation of the CCR6-CCL20 axis: a potential therapeutic target in inflammation and cancer. Medicina (Kaunas) 54, 88 (2018). · DOI
  31. Wang, D. et al. Colorectal cancer cell-derived CCL20 recruits regulatory T cells to promote chemoresistance via FOXO1/CEBPB/NF-κB signaling. J. Immunother. Cancer 7, 215 (2019). · DOI
  32. Rébé, C. & Ghiringhelli, F. Interleukin-1β and cancer. Cancers 12, 1791 (2020). · DOI
  33. Ridker, P. M. et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 390, 1833–1842 (2017). · DOI · Paper page
  34. Bruchard, M. et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat. Med. 19, 57–64 (2013). · DOI
  35. Martínez-Reza, I. et al. Calcitriol inhibits the proliferation of triple-negative breast cancer cells through a mechanism involving the proinflammatory cytokines IL-1 β and TNF- α. J. Immunol. Res. 2019, 6384278 (2019). · DOI
  36. Mitsunaga, S. et al. Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer. Br. J. Cancer 108, 2063–2069 (2013). · DOI
  37. Kim, J.-W. et al. Clinical implications of VEGF, TGF-β1, and IL-1β in patients with advanced non-small cell lung cancer. Cancer Res. Treat. 45, 325–333 (2013). · DOI

Cited by

Sorted by citations

Metadata

Authors
Bruchard, M., Geindreau, M., Perrichet, A., Truntzer, C., Ballot, E., Boidot, R., Racoeur, C., Barsac, E., Chalmin, F., Hibos, C., Baranek, T., Paget, C., Ryffel, B., Rébé, C., Paul, C., Végran, F., & Ghiringhelli, F.
ORCID
Venue
Nature Immunology
Publisher
Springer Science and Business Media LLC
Published
2022-01-31
Volume
23
Issue
2
Pages
262-274
ISSN
  • 1529-2908
  • 1529-2916
DOI
10.1038/s41590-021-01120-y
Cited by
106
References
7
Language
en
Licence
Funders
  • Association pour la Recherche Thérapeutique Anti-Cancéreuse
  • fondation de francefondation ligue contre le cancer
  • Agence Nationale de la Recherche (ANR-11-LABX0021)
  • Labex LipSTIC

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review